Related Experiment Video

Updated: Jul 4, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Dauricine Inhibits Non-small Cell Lung Cancer Development by Regulating PTEN/AKT/mTOR and Ras/MEK1/2/ERK1/2 Pathways

Jinna Liang1,2, Panpan Lei1,2, Xinyue Su1,2

  • 1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, P.R. China.

Current Cancer Drug Targets
|February 7, 2024
PubMed
Abstract

Insights

Dauricine effectively inhibits non-small cell lung cancer (NSCLC) growth and migration by targeting vascular endothelial growth factor receptor 3 (FLT4). This study highlights dauricine as a potential therapeutic agent for NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) presents significant challenges due to its high malignancy and poor prognosis.
  • Vascular endothelial growth factor receptor 3 (FLT4, also known as VEGFR3) is overexpressed in NSCLC cells, identifying it as a potential therapeutic target.

Purpose of the Study:

  • To investigate the anti-cancer effects of dauricine on NSCLC cells.
  • To elucidate the mechanism by which dauricine exerts its effects, specifically its targeting of FLT4.

Main Methods:

  • Flow cytometry was used to analyze cell cycle progression.
  • Wound healing and transwell migration assays assessed cell migration.
  • FLT4 protein levels were correlated with dauricine's anti-cancer effects, and FLT4 knockdown was performed to validate its role.

Main Results:

  • Dauricine inhibited NCI-H1299 cell growth by arresting the cell cycle at the G2/M phase.
  • Dauricine significantly reduced NCI-H1299 cell migration.
  • A positive correlation was observed between dauricine's anti-cancer activity and FLT4 protein levels, which was diminished upon FLT4 knockdown.

Conclusions:

  • Dauricine demonstrates anti-cancer effects on NSCLC cells by targeting FLT4.
  • Dauricine modulates downstream signaling pathways including PTEN/AKT/mTOR and Ras/MEK1/2/ERK1/2.
  • Dauricine regulates key molecules involved in cell migration (MMP3) and cell cycle progression (CDK1, pCDK1-T161, cyclin B1).
  • Dauricine shows promise as a potential FLT4 inhibitor for NSCLC treatment.
Keywords:
FLT4NSCLCVEGFR3cell growthcell migration.dauricine

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K